CN1514727A - 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节 - Google Patents

在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节 Download PDF

Info

Publication number
CN1514727A
CN1514727A CNA028116720A CN02811672A CN1514727A CN 1514727 A CN1514727 A CN 1514727A CN A028116720 A CNA028116720 A CN A028116720A CN 02811672 A CN02811672 A CN 02811672A CN 1514727 A CN1514727 A CN 1514727A
Authority
CN
China
Prior art keywords
trans
benzodioxole
methyl
pyrrolidine
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028116720A
Other languages
English (en)
Chinese (zh)
Inventor
A
A·辛
R·J·帕利
T·阿斯拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1514727A publication Critical patent/CN1514727A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028116720A 2001-04-11 2002-04-11 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节 Pending CN1514727A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/832,752 2001-04-11
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US11848602A 2002-04-08 2002-04-08
US10/118,486 2002-04-08

Publications (1)

Publication Number Publication Date
CN1514727A true CN1514727A (zh) 2004-07-21

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028116720A Pending CN1514727A (zh) 2001-04-11 2002-04-11 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节

Country Status (10)

Country Link
EP (1) EP1379238A1 (pt)
JP (1) JP2005503339A (pt)
CN (1) CN1514727A (pt)
AR (1) AR033465A1 (pt)
BR (1) BR0205970A (pt)
CA (1) CA2442591A1 (pt)
IL (1) IL158071A0 (pt)
MX (1) MXPA03009277A (pt)
PE (1) PE20021032A1 (pt)
WO (1) WO2002085351A1 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011596A1 (zh) * 2021-08-05 2023-02-09 中国药科大学 酰胺类化合物及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
WO2007133796A2 (en) * 2006-05-15 2007-11-22 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
US20090054473A1 (en) 2007-08-22 2009-02-26 Gilead Colorado, Inc. Therapy for complications of diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL342500A1 (en) * 1997-08-04 2001-06-04 Abbott Lab Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011596A1 (zh) * 2021-08-05 2023-02-09 中国药科大学 酰胺类化合物及其应用

Also Published As

Publication number Publication date
JP2005503339A (ja) 2005-02-03
BR0205970A (pt) 2003-09-30
PE20021032A1 (es) 2002-11-12
WO2002085351A1 (en) 2002-10-31
AR033465A1 (es) 2003-12-17
EP1379238A1 (en) 2004-01-14
MXPA03009277A (es) 2004-03-10
IL158071A0 (en) 2004-03-28
CA2442591A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CN1177833C (zh) 取代的间二氮杂萘衍生物
US20200222413A1 (en) Methods of treatment using selective bcl-2 inhibitors
CN1101392C (zh) 抑制法呢基蛋白质转移酶的(咪唑－5－基)甲基－2－喹啉酮衍生物
CN1309711C (zh) 3－酰氨基－1,2－苯并异噁唑衍生物、其制备方法及应用
CN1308535A (zh) 供治疗关节病的法呢基(Farnesyl)蛋白质转移酶抑制剂
CN1400904A (zh) 与雌激素联合的选择性雌激素受体调节剂
CN1735416A (zh) 治疗剂组合
CN101035536A (zh) 有机化合物的组合
JP2003529563A (ja) ビュープロピオン代謝産物並びにその合成および使用方法
CN1215338A (zh) 包含具有血管紧张素ⅱ拮抗活性的化合物的药物组合物
JP2009526821A (ja) 注意欠陥多動性障害治療用の新規な医薬組成物
CN1838959A (zh) Erbb2抗癌剂的给药方案
CN101065127A (zh) 包含埃博霉素和蛋白酪氨酸激酶抑制剂的组合产品及其药物用途
CN1455769A (zh) 用作β－3肾上腺素能受体激动剂的环胺磺酰胺
CN1158283C (zh) 作为蛋白激酶抑制剂的4-和5-吡嗪基羟吲哚
CN1514727A (zh) 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节
CN1874776A (zh) 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈
US20030092757A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
CN100341509C (zh) 用于改善血液中脂质或降低血液中高半胱氨酸的药物组合物
CN1254243C (zh) 包含白屈菜碱或其衍生物的药物组合物
CN1218698C (zh) 用于治疗和预防肝纤维化和肝硬化的药物组合物
CN1709257A (zh) 治疗高血脂症的组合物
CN1247198C (zh) 治疗高血脂症的组合物
CN1571669A (zh) 新的联用产品
CN1307996C (zh) 治疗高血脂症的组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned